1. Periostin in Angiogenesis and Inflammation in CRC-A Preliminary Observational Study.
- Author
-
Kula A, Dawidowicz M, Mielcarska S, Kiczmer P, Chrabańska M, Rynkiewicz M, Świętochowska E, and Waniczek D
- Subjects
- Diagnostic Tests, Routine, Enzyme-Linked Immunosorbent Assay, Humans, Interferon-gamma, Cell Adhesion Molecules blood, Colorectal Neoplasms diagnosis, Cytokines blood, Inflammation
- Abstract
Background and Objectives : To assess the periostin level and the concentrations of pro-inflammatory cytokines: TNFα, IFN-γ, IL-1β and IL-17 in tumor and marginal tissues of CRC and to investigate the influence of periostin on angiogenesis by MVD (microvessel density) and concentration of VEGF-A in relation to clinicopathological parameters of patients. Materials and Methods : The study used 47 samples of tumor and margin tissues derived from CRC patients. To determinate the concentration of periostin, VEGF-A, TNFα, IFNγ, IL-1β and IL-17, we used the commercially available enzyme- linked immunosorbent assay kit. MVD was assessed on CD34-stained specimens. The MVD and budding were assessed using a light microscope Results : Periostin activity may be associated with pro-inflammatory cytokine levels: TNFα, IFN-γ, IL-1β and IL-17. Our results also suggest the role of periostin in angiogenesis in CRC and its upregulation in poorly vascularized tumors. Further research on the regulations between periostin and cytokines are necessary to understand the interactions between tumor and immune tumor microenvironment, which could be helpful in the development of new targeted therapy.Conclusions: Periostin activity may be associated with pro-inflammatory cytokine levels: TNFα, IFN-γ, IL-1β and IL-17. Our results also suggest the role of periostin in angiogenesis in CRC and its upregulation in poorly vascularized tumors. Further research on the regulations between periostin and cytokines are necessary to understand the interactions between tumor and immune tumor microenvironment, which could be helpful in the development of new targeted therapy.
- Published
- 2022
- Full Text
- View/download PDF